Lantern Pharma announced the appointment of David Margrave as Chief Financial Officer and Kishor Gopaldas Bhatia as Chief Scientific Officer.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.505 USD | -1.34% | -11.52% | +29.21% |
05-29 | Transcript : Lantern Pharma Inc. - Special Call | |
05-24 | Lantern Pharma Files $150 Million Mixed Shelf | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.21% | 60.03M | |
+47.78% | 57.87B | |
+41.65% | 40.25B | |
-6.99% | 39.94B | |
-5.96% | 28.54B | |
+12.14% | 26.4B | |
-20.48% | 19.33B | |
+30.13% | 12.4B | |
-0.79% | 12.23B | |
+24.08% | 12.2B |
- Stock Market
- Equities
- LTRN Stock
- News Lantern Pharma Inc.
- Lantern Pharma Inc. Announces Executive Changes